Friday, April 07, 2017 12:32:15 PM
So I got the phone call last night asking me about how I will be voting my shares with respect to the proxy vote for AVXL.
The gentleman really don't know anything. When I asked why do they want to be able to issue preferred shares he responded by reading the prospectus. When I asked again why they needed another method of financing when they still have over 50 million common shares which can be issued without a shareholder vote he referred to the Lincoln Park deal and read about the $50 million dollars of stock AVXL can sell to Lincoln Park... basically read the agreement to me. I then asked again why they need authorization to issue 10M preferred shares when they can still issue over 50 million common. He went back to the $50M Lincoln Park deal and started reading the prospectus again. I politely interrupted this time and pointed at that even at $5 per share the Lincoln Park deal is only going to increase the outstanding share count by 10 million and that some had already been issued... and that this still leaves 45-50M that they can still issue without a share holder vote. He fumbled a bit and started reading portions of the prospectus on what the proceeds of the 10 million might be used for. The only thing I got out of this call was he read several times that the 10 million preferred might be used for mergers and acquisitions... but this is really just boiler plate. So if we vote yes we are really trusting Dr. Missling and the board to do the right thing with the shares.
I told him I wanted to think about it for a couple more days. He is going to call me on again on Monday.
I have no clue if anything is going on behind the scenes but it is interesting that AVXL really wants the authority to issue the 10M preferred... even though they can still issue ~55M common. Someone posted on here that maybe the preferred are to be issued to a BP company (BIIB?) that might want to by into some equity of AVXL. Could be but we really have no way of knowing.
Cheers.
GO AVXL.
The gentleman really don't know anything. When I asked why do they want to be able to issue preferred shares he responded by reading the prospectus. When I asked again why they needed another method of financing when they still have over 50 million common shares which can be issued without a shareholder vote he referred to the Lincoln Park deal and read about the $50 million dollars of stock AVXL can sell to Lincoln Park... basically read the agreement to me. I then asked again why they need authorization to issue 10M preferred shares when they can still issue over 50 million common. He went back to the $50M Lincoln Park deal and started reading the prospectus again. I politely interrupted this time and pointed at that even at $5 per share the Lincoln Park deal is only going to increase the outstanding share count by 10 million and that some had already been issued... and that this still leaves 45-50M that they can still issue without a share holder vote. He fumbled a bit and started reading portions of the prospectus on what the proceeds of the 10 million might be used for. The only thing I got out of this call was he read several times that the 10 million preferred might be used for mergers and acquisitions... but this is really just boiler plate. So if we vote yes we are really trusting Dr. Missling and the board to do the right thing with the shares.
I told him I wanted to think about it for a couple more days. He is going to call me on again on Monday.
I have no clue if anything is going on behind the scenes but it is interesting that AVXL really wants the authority to issue the 10M preferred... even though they can still issue ~55M common. Someone posted on here that maybe the preferred are to be issued to a BP company (BIIB?) that might want to by into some equity of AVXL. Could be but we really have no way of knowing.
Cheers.
GO AVXL.
Recent AVXL News
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
- Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference • GlobeNewswire Inc. • 11/26/2025 12:30:00 PM
